CATALYST PHARMACEUTICALS, INC.CPRXEarnings & Financial Report
Catalyst Pharmaceuticals, Inc. is a biopharmaceutical company based in Coral Gables, Florida, United States. The company develops medicines for rare diseases, including the phosphate salt of amifampridine for the treatment of Lambert–Eaton myasthenic syndrome (LEMS). The drug is referred to under the trade name Firdapse, which was approved by the FDA for approved use in children 6 years and older with LEMS in addition to the prior approval for use in adults with LEMS on November 28, 2018. Fir...
CPRX Q3 2025 Key Financial Metrics
Revenue
$148.4M
Gross Profit
$125.7M
Operating Profit
$66.3M
Net Profit
$52.8M
Gross Margin
84.7%
Operating Margin
44.7%
Net Margin
35.6%
YoY Growth
15.3%
EPS
$0.42
Financial Flow
CATALYST PHARMACEUTICALS, INC. Q3 2025 Financial Summary
CATALYST PHARMACEUTICALS, INC. reported revenue of $148.4M for Q3 2025, with a net profit of $52.8M (35.6% margin). Cost of goods sold was $22.7M, operating expenses totaled $59.5M.
Key Financial Metrics
| Total Revenue | $148.4M |
|---|---|
| Net Profit | $52.8M |
| Gross Margin | 84.7% |
| Operating Margin | 44.7% |
| Report Period | Q3 2025 |
CATALYST PHARMACEUTICALS, INC. Annual Revenue by Year
CATALYST PHARMACEUTICALS, INC. annual revenue history includes year-by-year totals (for example, 2024 revenue was $491.7M).
| Year | Annual Revenue |
|---|---|
| 2024 | $491.7M |
| 2023 | $398.2M |
| 2022 | $214.2M |
Income Statement
| Q4 2023 | Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $110.6M | $98.5M | $122.7M | $128.7M | $141.8M | $141.4M | $146.6M | $148.4M |
| YoY Growth | 82.0% | 15.4% | 23.2% | 25.3% | 28.3% | 43.6% | 19.4% | 15.3% |
Balance Sheet
| Q4 2023 | Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | |
|---|---|---|---|---|---|---|---|---|
| Assets | $470.1M | $646.7M | $706.4M | $772.0M | $851.4M | $908.9M | $971.9M | $1.05B |
| Liabilities | $82.2M | $85.3M | $97.7M | $111.1M | $123.8M | $114.6M | $115.9M | $131.4M |
| Equity | $387.9M | $561.4M | $608.7M | $660.9M | $727.6M | $794.3M | $856.0M | $920.2M |
Cash Flow
| Q4 2023 | Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | |
|---|---|---|---|---|---|---|---|---|
| Operating CF | $55.6M | $31.9M | $64.1M | $72.9M | $70.9M | $60.0M | $71.3M | $32.4M |
More Companies
ILMN
ILLUMINA, INC.
Revenue
$1.2B
Net Profit
$334.0M
UTHR
UNITED THERAPEUTICS Corp
Revenue
$799.5M
Net Profit
$338.7M
GMAB
GENMAB A/S
Revenue
$925.0M
Net Profit
$336.0M
GH
Guardant Health, Inc.
Revenue
$265.2M
Net Profit
$-92.7M
NBIX
NEUROCRINE BIOSCIENCES INC
Revenue
$805.5M
Net Profit
$153.7M
EXEL
EXELIXIS, INC.
Revenue
$598.7M
Net Profit
$244.5M
MDGL
MADRIGAL PHARMACEUTICALS, INC.
Revenue
$287.3M
Net Profit
$-114.2M
QGEN
QIAGEN N.V.
BMRN
BIOMARIN PHARMACEUTICAL INC
Revenue
$776.1M
Net Profit
$-30.7M
ARWR
ARROWHEAD PHARMACEUTICALS, INC.
Revenue
$264.0M
Net Profit
$30.8M